GlassScriptPhysician profile
Irena Culic
NPI 1023308269
$12,800.95
in general payments reported to CMS, 2019-2025
28 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,443 · 2022: $2,177 · 2023: $3,953 · 2024: $2,975 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,274 · Consulting Fee: $1,750 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,274.22 |
| Consulting Fee | $1,750.00 |
| Education | $157.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,327.08 | 2021-2025 | Bimzelx, Cimzia, Briviact |
| Amgen INC. | $1,672.38 | 2021-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $1,633.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,047.87 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $897.83 | 2022-2025 | Sotyktu |
| Pfizer INC. | $879.38 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $565.59 | 2021-2024 | Dupixent |
| Janssen Biotech, INC. | $508.74 | 2021-2025 | Tremfya |
| Genzyme Corporation | $501.73 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $483.69 | 2022-2025 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $471.47 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $418.52 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $403.72 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $345.97 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $86.89 | 2023-2025 | Nemluvio, Oracea, Epsolay |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $81.04 | 2022-2024 | Vtama |
| Organon LLC | $80.41 | 2023-2025 | Hadlima, Vtama |
| Almirall LLC | $79.14 | 2021-2024 | Klisyri |
| Botanix Sb INC | $52.93 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.29 | 2021-2023 | Duobrii, Arazlo, Jublia |
| Solta Medical, A Division of Bausch Health US, LLC | $44.69 | 2024-2025 | Fraxel, Clear & Brilliant |
| Kyowa Kirin, INC. | $37.90 | 2023-2024 | Poteligeo |
| Springworks Therapeutics, INC. | $35.04 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.94 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $20.11 | 2023 | Idacio |
| Biofrontera INC. | $19.29 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.33 | 2023 | Givlaari |
| Journey Medical Corporation | $14.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irena Culic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.